Abivax S.A.
ABVX.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | €2 | €4 | €7 | €2 |
| % Growth | -49.7% | -41% | 202.3% | – |
| Cost of Goods Sold | €0 | €1 | €0 | €0 |
| Gross Profit | €2 | €4 | €7 | €2 |
| % Margin | 100% | 100% | 100% | 83.2% |
| R&D Expenses | €78 | €82 | €65 | €71 |
| G&A Expenses | €16 | €15 | €18 | €16 |
| SG&A Expenses | €18 | €17 | €22 | €22 |
| Sales & Mktg Exp. | €2 | €2 | €4 | €6 |
| Other Operating Expenses | -€0 | -€2 | -€0 | -€0 |
| Operating Expenses | €96 | €97 | €87 | €92 |
| Operating Income | -€94 | -€105 | -€80 | -€90 |
| % Margin | -4,645.3% | -2,631.9% | -1,178.9% | -4,016.8% |
| Other Income/Exp. Net | -€7 | €7 | -€4 | -€6 |
| Pre-Tax Income | -€101 | -€99 | -€84 | -€96 |
| Tax Expense | €0 | -€4 | -€3 | €0 |
| Net Income | -€101 | -€95 | -€82 | -€96 |
| % Margin | -4,996.7% | -2,361.6% | -1,203% | -4,266.7% |
| EPS | -1.59 | -1.5 | -1.3 | -1.91 |
| % Growth | -6% | -15.4% | 31.9% | – |
| EPS Diluted | -1.59 | -1.5 | -1.3 | -1.91 |
| Weighted Avg Shares Out | 63 | 63 | 63 | 50 |
| Weighted Avg Shares Out Dil | 63 | 63 | 63 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €3 | €5 | €2 |
| Interest Expense | €4 | €6 | €8 | €6 |
| Depreciation & Amortization | €0 | €1 | €0 | €0 |
| EBITDA | -€94 | -€92 | -€80 | -€90 |
| % Margin | -4,640.3% | -2,292.7% | -1,176.3% | -4,011% |